Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Replimune Group, Inc. - Common Stock
(NQ:
REPL
)
8.800
+0.380 (+4.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Replimune Group, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
FDA Rejects Replimune's Blood Cancer Drug, Stock Sinks
July 22, 2025
Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.
Via
Benzinga
Which stocks are moving before the opening bell on Tuesday?
July 22, 2025
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
July 22, 2025
Via
Benzinga
Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
July 22, 2025
From
Replimune, Inc.
Via
GlobeNewswire
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 11, 2025
From
Replimune, Inc.
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
June 12, 2025
Via
Benzinga
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
June 01, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Replimune to Present at the 2025 Jefferies Global Healthcare Conference
May 29, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
May 22, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Earnings Scheduled For May 22, 2025
May 22, 2025
Via
Benzinga
Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day
May 16, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 09, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
April 21, 2025
Via
Benzinga
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 07, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
February 12, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session
February 10, 2025
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 10, 2025
Via
Benzinga
Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
February 10, 2025
Via
Benzinga
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Nasdaq Jumps 100 Points; Charles Schwab Profit Beats Estimates
January 21, 2025
Via
Benzinga
Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday
January 21, 2025
Via
Benzinga
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
January 21, 2025
PDUFA action date of July 22, 2025, with priority review
From
Replimune Group Inc
Via
GlobeNewswire
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials
January 08, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 23, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Replimune Announces Pricing of Upsized Public Offering
November 25, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Replimune Announces Proposed Public Offering
November 25, 2024
From
Replimune Group Inc
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
November 22, 2024
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.